The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine comprises multiple effector mechanisms.
Listeria monocytogenes, a facultative intracellular bacterium, can induce a potent antitumor immune response if engineered to express a model tumor antigen also expressed by the tumor cells. The effectiveness of this approach is dependent on L. monocytogenes-induced tumor-specific CD4(+) and CD8(+) T-cells. CD8(+) T-cells may mediate tumor eradication largely through direct CTL activity, but the role of CD4(+) T-cells and other cells of the immune system is less clear. Here we investigate their role and the role of the cytokines they produce in the ability of L. monocytogenes-induced antitumor immunity to protect against tumor challenge. Our results suggest that a complex cytokine response, involving type 2 as well as type 1 cytokines, is responsible for the ability of Lm-NP-immunized mice to resist tumor challenge, potentially mediating tumor cell killing through multiple effector pathways.
Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, 19104-6076, USA.
L M
LM
Weiskirch
Z K
ZK
Pan
Y
Y
Paterson
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology*; D003713:Dendritic Cells / Q000502:physiology; D007114:Immunization; D015847:Interleukin-4 / Q000502:physiology; D008089:Listeria monocytogenes / Q000276:immunology*; D008213:Lymphocyte Activation; D008264:Macrophages / Q000502:physiology; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology*
D000951:Antigens, Neoplasm; D001428:Bacterial Vaccines; D014614:Vaccines, Synthetic; D015847:Interleukin-4